Dividend Stocks

The Dividend Daily

Dividend stocks - News, notes, updates, and analysis, delivered fresh daily

Goldman Sachs Upgrades Mead Johnson to “Conviction Buy” (MJN)

Children’s nutrition and food maker Mead Johnson Nutrition Co. (MJN) was upgraded by Goldman Sachs analysts on Monday, as the company is expected to build momentum in 2013 and raise earnings estimates.

The analysts upgraded MJN from “Neutral” to “Conviction Buy.” The firm also boosted its price target for the children’s nutrition company from $75 to $95, which suggests a +27% upside to Friday’s closing price of $75.05.

A Goldman Sachs analyst commented, “Despite MJN’s recent set-back in China, which was followed by below-consensus guidance, we believe it uniquely positioned to deliver best-in-class growth and returns. As we detail within, we believe milk formula sales will expand by $46 bn to 2020 globally (11% CAGR) and expect MJN to capture its fair share.”

The analysts also raised MJN EPS estimates. The company is now expected to earn $3.42 per share in 2013, $4.00 in 2014, and $4.74 in 2015.

Mead Johnson shares were flat during pre-market trading on Monday. The stock is down -0.24% over the past year.

The Bottom Line
Shares of Mead Johnson (MJN) have a dividend yield of 1.60% based on Friday’s closing price of $75.05.

Mead Johnson Nutrition Co. (MJN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

5 Rules of Winning Dividend Investing

FREE Dividend Stock Newsletter

Get the Dividend.com email newsletter to receive:

  • A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
  • Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
  • Tons of great market analysis and recommendations

Your Email

Free Dividend Newsletter

Get free dividend tips, analysis and updates straight to your inbox

Comments on this Article COMMENTS ON THIS ARTICLE

Comments are closed.

About This Article ABOUT THIS ARTICLE

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Disclaimer: Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.